Caidya

Caidya is a privately held, full-service clinical research organization (CRO) founded in 2019 and headquartered in San Francisco, USA. It operates as a service provider to biopharma companies, offering end-to-end clinical development support from early phase through Phase II/III studies, with a strong focus on complex and specialized therapeutic areas like oncology, rare diseases, and cell & gene therapy. The company emphasizes a partnership model, global patient access, and the integration of technology and data analytics, including AI principles, to enhance trial delivery and quality. As a service business, it is revenue-generating, with its success tied to the broader biopharmaceutical R&D outsourcing market.

Integrated clinical technology ecosystem encompassing biometrics, clinical data management, analytics (including 'Clarity'), and RBQM, guided by formal AI principles to enhance trial design, execution, and data quality.

Caidya operates in the highly competitive global CRO market, competing against large, full-service players like IQVIA, ICON, and Labcorp, as well as numerous mid-sized and niche CROs. Its differentiation is based on a client-partnership model, deep therapeutic expertise in specific areas, and the integration of technology and AI, rather than scale alone.